Europe Needs More Patient Capital To Nurture Biotechs
Executive Summary
Analysis by the European Investment Bank predicts that EU biotechs face a funding shortfall of up to €40bn by 2021. Barbara Freischem, executive director of European Biopharmaceutical Enterprises, who moderated a panel on the topic at BIO-Europe Spring 2018, talked to Scrip about initiatives that could alleviate the shortfall.
You may also be interested in...
MIFID II May Hit Small & Midcap EU Biotech Investment
New EU regulation designed to offer greater protection and more transparency for investors could have serious implications for Europe’s small to midcap biotechs just as the European Investment Bank predicts a potential €40bn funding shortfall in key bioclusters by 2021.
Quality UK Biotechs Will Dodge Post-Brexit VC Drought
With the UK deadline to leave the European Union just over 12 months away, UK companies will see access to European Investment Fund-backed venture capital restricted. Quality companies, however, should not be fearful.
AI Firm Healx Raises $56M To Develop Affordable Rare Disease Treatments
Cambridge, UK-based Healx has concluded a $56m series B round, led by Atomico, to put up to 50 potential rare disease treatments into the clinic within two years using its AI/ML platform.